Muscle-related biology
Experiments included Long R3 IGF-1 in models of cancer-associated muscle wasting. Findings in cells and mice do not establish healthy muscle gain.
Read the publication
Physician-led care in the UAE
Peptide care · Pen
LR3-IGF1
Animal studies explore growth and muscle-related pathways. Human treatment benefits for LR3-IGF1 remain unestablished in the reviewed literature.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
Select the format
Get startedImportant safety informationSuitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Where LR3-IGF1
has been studied.
The recovery association comes from IGF biology and animal experiments, not controlled human evidence for muscle growth or rehabilitation.
Recovery questions
The biological pathway explains interest in recovery. Controlled human evidence demonstrating rehabilitation or fitness benefits was not identified in the reviewed sources.
Read the publicationSafety & suitability
Is LR3-IGF1 right for you?
A lack of controlled human evidence leaves substantial uncertainty about the risks and benefits of the proposed preparation.
Suitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
LR3-IGF1:
what has been studied.
The reviewed evidence is from laboratory and animal work. It does not establish muscle-building or recovery benefits in people.
The experiments included Long R3 IGF-1 and reported effects on some muscle measures.
Mouse models of cancer-associated wasting · Experimental treatment
What remains uncertain
Read the studyA mouse model of severe disease does not demonstrate healthy muscle gain or human treatment safety.
About this evidence review
Long R3 IGF-1 is a modified analog. Approval or studies of mecasermin cannot be transferred to LR3-IGF1.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss LR3-IGF1. Your clinician decides which preparation, checks and follow-up are relevant.
01
The preparation
What exactly are we considering?
What is the exact ingredient, formulation and strength, and how would it be used?
02
Your assessment
What needs checking first?
How would blood glucose, IGF-1 and my medical history affect the decision?
03
Your follow-up
How will we review the plan?
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is LR3-IGF1 considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
Which LR3-IGF1 format is right for me?
Long R3 IGF-1 is a modified analog. Approval or studies of mecasermin cannot be transferred to LR3-IGF1.
What should I know about the safety of LR3-IGF1?
A lack of controlled human evidence leaves substantial uncertainty about the risks and benefits of the proposed preparation.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
More in this area.
Explore other compounds discussed in these health topics, with the evidence for each.
DarDoc peptidesRecovery · Skin & hair · Digestive health
BPC-157
Early human reports describe improvements in specific pain and bladder conditions. The preparation and treatment site matter.
DarDoc peptidesRecovery · Skin & hair
Thymosin Beta-4
The studies reviewed here examined wound healing and short-term tolerability. Their findings apply to the preparations and outcomes studied.
DarDoc peptidesRecovery · Metabolism
CJC 1295
Controlled studies show that long-acting CJC-1295 can increase growth hormone and IGF-1 levels in healthy adults.
Bring your questions
Make your next step
a conversation.
Want to understand where LR3-IGF1 fits? Discuss the evidence, your health history and the options with DarDoc.
